biology-technology-1/yongye-international-announces-conference-call-to-discuss-third-quarter-2009-results-14768-2/;msg90356

Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2 BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2 BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4

[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer [0] BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement [0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year

Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3 Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 1 Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 2 LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 1 LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 2

[0] Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting [0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease [0] Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million